The primary objective of this review was to evaluate the antiviral efficacy of co-formulated zidovudine-lamivudine-abacavir (Trizivir®) for initial treatment of HIV infection. The secondary objectives were to evaluate the safety and tolerability of the triple drug combination. We identified nine potentially eligible studies, three of which met our inclusion criteria. Our findings indicate that Trizivir® remains a viable option for initiating antiretroviral therapy, especially in HIV-infected patients with pre-existing hyperlipidaemia and those who do not tolerate ritonavir.
Shey, M.; Kongnyuy, E.J.; Shang, J.; Wiysonge, C.S. A combination drug of abacavir-lamivudine-zidovudine (Trizivir®) for treating HIV infection and AIDS. Cochrane Database of Systematic Reviews (2009) (Issue 3) Art. No.: CD005481. [DOI: 10.1002/14651858.CD005481.pub2]
A combination drug of abacavir-lamivudine-zidovudine (Trizivir®) for treating HIV infection and AIDS